MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
p53 is one of the main regulators of apoptosis, senescence, cell cycle arrest and DNA repair. The expression, function and stabilization of p53 are governed by a complex network of regulators including p14(ARF) and MDM2. MDM2 is the main negative regulator of p53 activity and stability. Unlike tumours in adults, which tend to overcome p53 regulation by p53 mutations, the paediatric tumours neuroblastoma and sarcoma frequently retain wild type p53. Nevertheless, in childhood cancer the p53 pathway is commonly impaired due to upstream MDM2-p14(ARF)-p53 network aberrations. In contrast, aberrations of the p53 downstream pathway are very rare. In cancer cells with intact p53 downstream function MDM2 inhibition, and subsequent rapid increases in nuclear p53 levels, potently "re-activate" dormant apoptotic pathways and rapidly induce apoptotic cell death. As a result MDM2-p53 interaction inhibitors, including cis-imidazolines analogs (Nutlins), are potentially very effective agents in neuroblastoma and sarcomas. Predictive biomarkers are important as a lack of p53 mutations appears to reliably predict response to these inhibitors. Tumours should be screened for p53 mutations in children considered for MDM2-p53 interaction inhibitors. In addition, it is essential that other predictive biomarkers are investigated. The serum concentration of macrophage inhibitory cytokine- 1 (MIC-1) may be a good pharmacodynamic biomarker based on recent findings. In conclusion, targeting the interaction between p53 and its main negative regulator MDM2 represents a major new therapeutic approach in poor prognosis paediatric malignancies without p53 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835 · cited 1×
“18 anti-GD2, IL2 and GM-CSF to standard treatment has shown an increase in 2-year progressionfree survival to 60% and 2-year overall survival to 80% [19].”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“It has been proposed that both Rb and p53 pathways must be inactivated during cancer progression [88-90].”
BackgroundInactivation of the p53 pathway in retinoblastoma
Laurie, N. A., Donovan, S. L., Shih, C.-S., Zhang, J., Mills, N., Fuller, C., Teunisse, A., Lam, S., Ramos, Y., Mohan, A., et al. (2006) · Nature · doi:10.1038/nature05194 · Cited by 595
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · cited 11×
“In contrast, serum MIC-1 percentage changes from baseline, as well as TUNEL staining, correlated with drug exposure, as was reported for the first-in-man studies of RG7112 [81, 99- 101].”
BackgroundResultInfluentialMDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · cited 1×
“In cancer cells with intact p53 function (wild type p53 and a functional downstream pathway), MDM2 inhibition and subsequent rapid increases in nuclear p53 levels potently “reactivate” dormant apoptotic pathways and rapidly induce apoptotic cell death [9].”
BackgroundCoordinated regulation of life and death by RB
Chau, B. N., & Wang, J. Y. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc993 · Cited by 292 · cited 1×
“It has been proposed that both Rb and p53 pathways must be inactivated during cancer progression [88-90].”
BackgroundMichaelis, M., Rothweiler, F., Barth, S., Cinatl, J., van Rikxoort, M., Löschmann, N., Voges, Y., Breitling, R., von Deimling, A., Rödel, F., et al. (2011) · Cell Death & Disease · doi:10.1038/cddis.2011.129 · Cited by 190
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function
Lau, L. M. S., Nugent, J. K., Zhao, X., & Irwin, M. S. (2008) · Oncogene · doi:10.1038/sj.onc.1210707 · Cited by 182 · cited 1×
“Indeed methotrexate, cisplatin and doxorubicin showed various degrees of additivity or synergism, allowing up to 10fold dose reduction of conventional chemotherapeutic drugs when combined with Nutlin-3a, in line with other publications [60, 79, 80].”
ResultAmbrosini, G., Sambol, E. B., Carvajal, D., Vassilev, L. T., Singer, S., & Schwartz, G. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210136 · Cited by 163 · cited 1×
“Indeed methotrexate, cisplatin and doxorubicin showed various degrees of additivity or synergism, allowing up to 10fold dose reduction of conventional chemotherapeutic drugs when combined with Nutlin-3a, in line with other publications [60, 79, 80].”
ResultEfeyan, A., Ortega-Molina, A., Velasco-Miguel, S., Herranz, D., Vassilev, L. T., & Serrano, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0200 · Cited by 140
Cited by
Irwin, M. S., & Park, J. R. (2015) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.015 · Cited by 392
Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26064 · Cited by 36
“Similarly, the pharmacodynamic testing that we present is consistent with both the proposed mechanism of action of MK-8242 and with published data for other MDM2 inhibitors against pediatric preclinical models.[41] MK8242 induced TP53 and the TP53-regulated gene p21 in all tumor models with wild-type TP53, but not in…”
SHP2: a new target for pro‐senescence cancer therapies
Serrano, M. (2015) · The EMBO Journal · doi:10.15252/embj.201591616 · Cited by 12
“Another class of drugs that are showing promising results derives from Nutlin-3a, an inhibitor of MDM2, that stabilizes p53 and that also induces senescence in many cancer cells (Barone et al , 2014).”
Metadata
- Authors
- Barone, G., Tweddle, D., Shohet, J., Chesler, L., Moreno, L., Pearson, A., & Maerken, T.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2014-01-31
- Volume
- 15
- Issue
- 1
- Pages
- 114-123
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2149655582
- Cited by
- 46
- References
- 12
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. https://app.cochat.ai/papers/10.2174/13894501113149990194
- The paper
- Barone, G., Tweddle, D., Shohet, J., Chesler, L., Moreno, L., Pearson, A., & Maerken, T. (2014). MDM2-p53 Interaction in Paediatric Solid Tumours: Preclinical Rationale, Biomarkers and Resistance. Current Drug Targets. https://doi.org/10.2174/13894501113149990194
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.